Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Net revenues	$ 248,069	$ 177,026	$ 82,888
Cost of revenues	80,048	55,609	39,870
Impairment of field equipment			6,412
Gross profit	168,021	121,417	36,606
Operating costs and expenses:
Research, development and clinical trials	50,574	38,103	41,467
Sales and marketing	77,663	63,528	59,449
General and administrative	73,456	59,114	51,007
Total operating costs and expenses	201,693	160,745	151,923
Operating income (loss)	(33,672)	(39,328)	(115,317)
Financial income (expenses), net	(12,270)	(9,169)	(6,147)
Income (loss) before income taxes	(45,942)	(48,497)	(121,464)
Income taxes	17,617	13,165	10,381
Net income (loss)	$ (63,559)	$ (61,662)	$ (131,845)
Basic and diluted net income (loss) per ordinary share	$ (0.69)	$ (0.70)	$ (1.54)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share	91,828,043	88,546,719	85,558,448